Having Temporarily Suspended Disbelief, Would-Be Eradicatee Looks Forward to Still Uncertain Future ‘A perilous seduction’ Irrational exuberance might not be the sole domain of streets Broad and Wall. Speculation in AIDS futures has also seen quite a run over the…
Metabolic Disturbances in HIV Infection Find Friend Not Foe in Protease Inhibitor Regimens Refeeding paradox On May 20-21 the Office of AIDS Research (OAR) sponsored a conference, the first of its kind on AIDS wasting syndrome. Alongside Michael Marco and…
Roche Racks Up Millions In Early Saquinavir Sales While Unwitting Patients Prime Themselves for Protease X-Resistance Community cries for compensation Cynical, greedy, manipulative, opportunistic, penny-pinching, short-sighted, slipshod. Do these words come to mind when you think of Hoffmann-La Roche’s AIDS…
Panel Embraces Maximum Viral Suppression as Goal of Therapy; Drug Company Bonanza Creates Headaches for Third-Party Payers and AIDS Treatment Educators Eleventh hour backstage skullduggery stymied by unified community "And What Rough Beast, Its Hour Come Round at Last, Slouches…
Opportunistic Infections in the Era of HAART - A Report from the 4th Conference on Retroviruses HIV RNA as guide to risk Protease inhibitors (ritonavir, indinavir and nelfinavir) in combination with reverse transcriptase inhibitors (commonly referred to as "HAART," for…
HIV-Infected Kids Choke in the Dust of Adult Advances While Their Advocates Struggle to Maintain Funding Two to three year lag As the AIDS epidemic nears the end of its second decade, pediatric AIDS research has become a flash-point for…
When it comes to corporate positioning for protease inhibitor market share, every company has a yarn to spin. Merck loyalists insist that theirs be used first-line because it's so powerful and, "after all, really requires multiple mutations in order to…
Government Study Finds Protease Based Triple Combination Keeps Patients Alive Longer Than Double Nuke Changing the standard of care Results of AIDS Clinical Trials Group (ACTG) 320, one of the most important studies of triple-drug antiviral therapy in people with…
Eluding Public Scrutiny, Nelfinavir Becomes the Fourth Protease Inhibitor to Hit the Pharmacy Shelves Resistance enigma The US Food & Drug Administration (FDA), which will soon be under the control of Acting Commissioner Dr. Michael Friedman when Commissioner Dr. David…
"Very effective" therapies for: Pneumocystis pneumonia (PCP) tuberculosis (TB) cryptococcosis histoplasmosis "Effective, but toxic" therapies for: toxoplasmic encephalitis "Moderately effective" therapies for: Mycobacterium avium complex (MAC) cytomegalovirus (CMV) "No active treatments" for: cryptosporidiosis/microsporidiosis progressive multifocal leukoencephalopathy (PML)